Litcius/Paper detail

Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma

Hiroaki Kodama, Kazushige Wakuda, Michitoshi Yabe, Naoya Nishioka, Eriko Miyawaki, Taichi Miyawaki, Nobuaki Mamesaya, Takahisa Kawamura, Haruki Kobayashi, Shota Omori, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Toshiaki Takahashi

2020Investigational New Drugs35 citationsDOI

Topics & Concepts

OsimertinibMedicineInterstitial lung diseaseLung cancerDiscontinuationInternal medicineEpidermal growth factor receptorOncologyAdverse effectRetrospective cohort studyCancerLungErlotinibLung Cancer Treatments and MutationsGastric Cancer Management and OutcomesInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma | Litcius